Search for Open Studies

To inquire about current studies please contact us at:

1-800-533-1792

Bone and Blood Marrow Transplant Clinical Trials

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Conditions: Leukemia
Principal Investigator: Jorge Galvez-Silva
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05457556.


Phase I/II Trial: Engineered Donor Graft (Orca-Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients with Hematologic Malignancies (HM)

Conditions: Hematologic Malignancies
Principal Investigator: Jorge Galvez-Silva
Learn more at https://clinicaltrials.gov/study/NCT05322850.


A Phase II Pilot Trial to Estimate Survival After a Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation-Sequence (NGS) Minimal Residual Disease (MRD) Negative

Conditions: Lymphoblastic Leukemia
Principal Investigator: Jorge Galvez-Silva
Learn more at https://clinicaltrials.gov/study/NCT03509961.


A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia

Conditions: Aplastic Anemia
Principal Investigator: Jorge Galvez-Silva
Learn more at https://clinicaltrials.gov/study/NCT05600426.


Phase I/II trial: Engineered Donor Graft (Orca-Q) for Pediatric Hematopoietic Cell Transplant (HCT) Recipients with Hematologic Malignancies (HM)

Conditions: Hematologic Malignancies
Principal Investigator: Jorge Galvez-Silva
Learn more at https://clinicaltrials.gov/study/NCT05322850.


A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Conditions: Hematologic Malignancies
Principal Investigator: Jorge Galvez-Silva
Learn more at https://clinicaltrials.gov/study/NCT04904588.


Phase 2 study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT05828069.


Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Interventions: Transplants Stem Cells
Principal Investigator: Jorge Galvez-Silva
Learn more at https://clinicaltrials.gov/study/NCT01166009.


Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Principal Investigator: Jorge Galvez-Silva
Learn more at https://clinicaltrials.gov/study/NCT01166009.


Dermatology Clinical Trials

Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including A Single Open-Label Arm (6-11 Years) Study To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Certolizumab Pegol (Czp) In Pediatric Study Participants With Moderate To Severe Chronic Plaque Psoriasis (Pso)

Conditions: Psoriasis
Principal Investigator: Ana Duarte
Learn more at https://clinicaltrials.gov/study/NCT04123795.


Gastroenterology Clinical Trials

Open-Label Induction And Maintenance Study Of Oral Cp-690,550 (Tofacitinib) In Children With Moderately To Severely Active Ulcerative Colitis

Conditions: Ulcerative Colitis
Principal Investigator: Lina Maria Felipez
Learn more at https://clinicaltrials.gov/study/NCT04624230.


OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Conditions: Ulcerative Colitis
Principal Investigator: Lina Maria Felipez
Learn more at https://clinicaltrials.gov/study/NCT04624230.


A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis

Conditions: Ulcerative Colitis
Principal Investigator: Ana Paredes
Learn more at https://clinicaltrials.gov/study/NCT05507216.


Hematology and Oncology Clinical Trials

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Conditions: Leukemia
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT03007147.


A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Conditions: Leukemia
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT03959085.


Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Conditions: Leukemia
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT03817398.


A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Conditions: Leukemia
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT04293562.


An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation

Conditions: Leukemia
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT04203316.


Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Conditions: Leukemia
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT04726241.


A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Conditions: Medulloblastoma
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT02724579.


A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG)

Conditions: Glioma
Principal Investigator: Maggie Fader
Learn more at https://pubmed.ncbi.nlm.nih.gov/34838156/.


A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Conditions: Glioma
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT03871257.


A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) 

Conditions: Glioma
Principal Investigator: Ziad Khatib
Learn more at https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT04166409&r=1.


A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Conditions: Central Nervous System Tumors
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT04939597.


A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor 

Conditions: Central Nervous System Tumors
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT04684368.


A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features

Conditions: Medulloblastoma
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT05382338.


A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Conditions: Sarcoma
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT05235165.


A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Conditions: Sarcoma
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT05691478.


A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)

Conditions: Sarcoma
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT04994132.


A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Conditions: Sarcoma
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT05304585.


A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors 

Conditions: Germ Cell Tumor
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT03067181.


Phase 3 Accelerated BEP Trial: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Conditions: Germ Cell Tumor
Principal Investigator: Maggie Fader
Learn more at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114870/.


Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) – Phase 2/3

Conditions: Hepatic Malignancy
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT03017326.


A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Conditions: Hodgkin's Lymphoma
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT05675410.


Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Conditions: Wilms Tumor
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT04322318.


Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer 

Conditions: Childhood Cancer
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT05228275.


Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Conditions: Langerhans Cell Histiocytosis
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT05828069.


A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms

Conditions: B-Cell Neioplasms
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT05206357.


Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Either Single Cycle (Low-Risk Patients) Or Randomization (High Risk Patients) To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue

Conditions: Medulloblastoma
Principal Investigator: Ziad Khatib
Learn more at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237968/.


A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas

Conditions: Meningioma
Principal Investigator: Ziad Khatib
CRA: Michelin Janvier
Learn more at https://clinicaltrials.gov/study/NCT05130866.


A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma

Conditions: Neuroblastoma
Principal Investigator: Guillermo De Angulo
Learn more at https://clinicaltrials.gov/study/NCT02559778.


OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma

Conditions: Diffuse Midline Glioma
Principal Investigator: Ossama Maher
Learn more at https://clinicaltrials.gov/study/NCT05518838.


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Conditions: Solid tumors, non-Hodgkin lymphoma, or histiocytic disorders
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT03213704.


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Conditions: Solid tumors, non-Hodgkin lymphoma, or histiocytic disorders
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT03213652.


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Conditions: Solid tumors
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT04195555.


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Conditions: Tumor with Genomic Alterations
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT04284774.


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Conditions: Solid tumors
Principal Investigator: Ziad Khatib
Learn more at https://clinicaltrials.gov/study/NCT04320888.


Key Adverse Events after Childhood Cancer

Principal Investigator: Maggie Fader
Learn more at https://www.clinicaltrials.gov/study/NCT00082745.


Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT04322318.


Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Conditions: Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
Principal Investigator: Maggie Fader
CRA: Michelin Janvier
Learn more at https://www.clinicaltrials.gov/study/NCT03155620.


Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Conditions: Sarcoma
Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT05235165.


Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Conditions: Sarcoma
Principal Investigator: Maggie Fader
Learn more at https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-01012&r=1.


NIH Ex-Vivo (FIU) Adopting a Functional Precision Medicine Approach to Reduce Cancer Disparities in Hispanic and Black Children of Miami

Conditions: Cancers
Principal Investigator: Maggie Fader
Learn more at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138443/.


Prospective Non-Interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Conditions: Tumors Cancer
Principal Investigator: Ossama Maher
Learn more at https://clinicaltrials.gov/study/NCT04142437.


Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to provide access for patients with out of specification leukapheresis product and/or out of specification manufactured tisagenlecleucel (CTL019; Kymriah®)

Conditions: Leukemia
Principal Investigator: Guillermo De Angulo
Learn more at https://clinicaltrials.gov/study/NCT03601442.


Nephrology Clinical Trials

A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome

Conditions: Frequently Relapsing Nephrotic Syndrome
Principal Investigator: Ana Paredes
Learn more at https://clinicaltrials.gov/study/NCT05627557.


Renal Tumors Classification, Biology, and Banking Study

Principal Investigator: Maggie Fader
Learn more at https://clinicaltrials.gov/study/NCT00898365.


Neurology Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy

Conditions: Epilepsy
Principal Investigator: Matt Lallas
Learn more at https://clinicaltrials.gov/study/NCT05323734.


A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Conditions: Cerebral Palsy
Principal Investigator: Migvis Monduy
Learn more at https://clinicaltrials.gov/study/NCT05206513.


Early Access Program with Arimoclomol for the Treatment of Niemann-Pick disease Type C in the US

Conditions: Niemann-Pick
Principal Investigator: Paula Schleifer
Learn more at https://clinicaltrials.gov/study/NCT04316637.


Intrathecal 2-Hydroxypropyl-B-cyclodextin for Neurological Decline in Patients with Niemann-Pick Disease Type C1

Conditions: Niemann-Pick
Principal Investigator: Paula Schleifer
Learn more at https://pubmed.ncbi.nlm.nih.gov/28803710/.


Clinical Needs of Individuals with a Chromosome 15 Condition

Conditions: Angelman Syndrome
Principal Investigator: Paula Schleifer
Learn more at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040524/.


TS Alliance Tuberous Sclerosis Complex (TSC) Biosample Repository and Natural History Database

Conditions: Tuberous Sclerosis Complex
Principal Investigator: Paula Schleifer
Learn more at https://classic.clinicaltrials.gov/ct2/show/NCT05676099.


A Multicenter, Open-Label, Randomized, Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates with Repeated Electroencephalographic Neonatal Seizures

Conditions: Epilepsy
Principal Investigator: Anuj Jayakar
Learn more at https://clinicaltrials.gov/study/NCT04519645.


A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous Ganaxolone in status epilepticus Ganaxolone

Conditions: Epilepsy
Principal Investigator: Anuj Jayakar
Learn more at https://clinicaltrials.gov/study/NCT04391569.


A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study with a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Conditions: Epilepsy
Principal Investigator: Anuj Jayakar
Learn more at https://clinicaltrials.gov/study/NCT04666610.


RNS® System Responsive Thalamic Stimulation for Primary Generalized Seizures (NAUTILUS) Study

To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.

Conditions: Epilepsy
Interventions: Device: Responsive stimulation Device: Sham stimulation
Eligibility: 12 Years and older (Child, Adult, Older Adult )
Principal Investigator: Fajardo
Learn more at https://clinicaltrials.gov/study/NCT05147571.


Neurosurgery Clinical Trials

A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects.

Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible.

Conditions: Intracranial Tumors
Interventions: Device: ExAblate 4000 System
Eligibility: 8 Years to 22 Years
Principal Investigator: John Ragheb
Learn more at https://clinicaltrials.gov/study/NCT03028246.


Predicting Seizure Responsiveness to Neuromodulation Using Connectomic Profiling (Vagus Nerve Stimulation [VNS] Study)

Conditions: Epilepsy
Principal Investigator: Shelly Wang
Learn more at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995963/.


A Phase 2 dose-escalation study examining the safety, pharmacokinetics, and preliminary efficacy of ascending drug and energy dose combinations for sonodynamic therapy using SONALA-001 in combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in subjects with Diffuse Intrinsic Pontine Glioma (DIPG)

Conditions: Glioma
Principal Investigator: Toba Niazi
Learn more at https://clinicaltrials.gov/study/NCT05123534.


A Safety and Feasibility Study to Evaluate Blood Brain Barrier Disruption Using Exablate MR Guided Focused Ultrasound in Combination With Doxorubicin in Treating Pediatric Patients With Diffuse Intrinsic Pontine Gliomas (DIPG)

Conditions: Diffuse Intrinsic Pontine Gliomas
Principal Investigator: Toba Niazi
Learn more at https://clinicaltrials.gov/study/NCT05630209.


Psychology Clinical Trials

Sleep-dependent Negative Overgeneralization in Peri-pubertal Anxiety

Conditions: Anxiety
Principal Investigator: Dana McMakin
Learn more at https://clinicaltrials.gov/study/NCT03643848.


You can also search for current studies Nicklaus Children's Hospital is participating in ClinicalTrials.gov